Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Large U.S. Multi-Center Study Supports the Safety and Efficacy of Sirtex’s SIR-Spheres® microspheres

Published: Friday, January 25, 2013
Last Updated: Friday, January 25, 2013
Bookmark and Share
Large multi-center clinical study re-affirms the safety and efficacy of Selective Internal Radiation Therapy (SIRT) with SIR-Spheres® microspheres in patients with metastatic colorectal cancer.

The data were presented by lead investigator Andrew S. Kennedy, M.D., F.A.C.R.O., Director, Radiation Oncology Research Sarah Cannon Research Institute, Nashville, TN.

SIR-Spheres microspheres are manufactured by Sirtex and are the only fully FDA PMA approved microsphere radiation therapy for the treatment of colorectal liver metastases. The microspheres are administered via the hepatic artery, either alone, or in conjunction with systemic chemotherapy.

“Our goal with these studies was to evaluate the overall survival, tumor response and safety of using microsphere therapy in patients who are no longer responding to chemotherapy,” said Dr. Kennedy. “Patients in the study had a history of heavy pre-treatment and presented challenges in finding an effective treatment option. These research findings should help to further define the role of SIRT in helping to shrink or control the tumors and prolong patient survival.”

Multi-Institutional U.S. Study Overview

This investigator initiated study was a retrospective analysis of the outcomes in 548 patients with metastatic colorectal cancer treated with SIR-Spheres microspheres from July 2002 to December 2011 at 11 U.S. institutions.1 All patients had received prior chemotherapy, with more than 30% having also received prior liver surgery or ablation.

The authors reported median survivals of 13.0, 9.0 and 8.1 months, respectively, in patients who had received 1, 2 or 3+ prior lines of chemotherapy. There were no significant differences in the adverse event profiles between the three groups. Most patients (97.8%) spent less than 24 hours in the hospital with the most common Grade 3 side effects being abdominal pain (7%) and fatigue (6%). The authors concluded that SIRT with SIR-Spheres microspheres appears to have a favorable risk/benefit ratio in patients with metastatic colorectal cancer who have failed chemotherapy. These data show a clinically relevant survival benefit in patients not responding to chemotherapy, including those who have been heavily pre-treated.

Independent Imaging Study Confirms Efficacy with SIRT

The second presentation from this study illustrated the response to SIRT therapy with SIR-Spheres microspheres from an imaging perspective.2 The study presented the results of an independent central review by a board-certified radiologist of 195 patients with metastatic colorectal cancer that were treated with SIR-Spheres microspheres and had measureable lesions at baseline and follow-up imaging. Tumor RECIST response at three months showed a Partial Response in 7.6% of patients, 47.3% experienced Stable Disease and 45.0% had Progressive Disease resulting in a Disease Control Rate of 55.0%. RECIST response at three months predicted median survival of 25.2 months in Partial Responders compared to 15.8 months in those with Stable Disease and 7.1 months with Progressive Disease.

Researchers noted that response to SIRT therapy at three months must be interpreted with caution due to the significant proportions of peri-tumoral edema and necrosis encountered. Both imaging findings may lead to either the underestimation of Partial Response/Stable Disease or the overestimation of Progressive Disease, respectively. Given these caveats, early hepatic radiological response to SIRT therapy appears to predict longer-term prognosis.

“These studies add to the growing body of scientific data further supporting the role of SIRT in treating metastatic colorectal cancer. In this specific patient population, the results compare favorably to many of recently approved chemotherapy and biologic agents, and provide another option to patients who may have stopped responding to systemic therapy,” said Mike Mangano, president of Sirtex Medical Inc. “It is our intention to continue to study SIR Spheres microspheres in various patient populations, with the goal of adding this treatment to conventional chemotherapy even earlier in the treatment algorithm. The SIRFLOX study, which is expected to complete enrollment in the first quarter of 2013, will test this hypothesis with the hope that controlling liver tumors will allow patients to live longer and experience an improved quality of life. We look forward to those results.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos